Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report)'s stock price dropped 6.3% during trading on Friday . The company traded as low as $13.02 and last traded at $13.04. Approximately 1,236,334 shares traded hands during mid-day trading, a decline of 8% from the average daily volume of 1,350,719 shares. The stock had previously closed at $13.91.
Ginkgo Bioworks Price Performance
The stock has a market cap of $823.10 million, a price-to-earnings ratio of -1.09 and a beta of 1.16. The firm's fifty day simple moving average is $10.57.
Institutional Trading of Ginkgo Bioworks
Institutional investors have recently bought and sold shares of the business. KBC Group NV purchased a new stake in Ginkgo Bioworks during the fourth quarter worth approximately $31,000. Algert Global LLC purchased a new stake in shares of Ginkgo Bioworks during the 2nd quarter worth approximately $36,000. Palumbo Wealth Management LLC acquired a new position in shares of Ginkgo Bioworks in the 4th quarter valued at $144,000. Y Intercept Hong Kong Ltd acquired a new stake in Ginkgo Bioworks during the 4th quarter worth $154,000. Finally, SG Americas Securities LLC acquired a new position in Ginkgo Bioworks in the fourth quarter valued at $199,000. 78.63% of the stock is owned by hedge funds and other institutional investors.
Ginkgo Bioworks Company Profile
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
See Also
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
